Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dAMD-3
- Development stage
- Preclinical
- Lead developer
- insitro
- Administration
- Ophthalmic
01
Overview
dAMD-3 is a preclinical therapeutic candidate being developed by insitro for the treatment of dry age-related macular degeneration (dAMD). The asset was identified using insitro's proprietary discovery platform, which integrates machine learning, human genetics, and high-content cellular data to uncover novel disease drivers. As part of insitro's ophthalmology pipeline, dAMD-3 is aimed at addressing the underlying biological mechanisms of retinal degeneration and geographic atrophy. While the specific molecular target and modality have not been publicly disclosed, the program represents the company's application of its 'insitro-readout' (ISRO) approach to complex ocular diseases.
Beyond the preview
Go deeper on dAMD-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dAMD-3.